Writing for Business of Cannabis, Scott Mazza, co-founder of Vitality CBD, argues that the federal spending bill provision capping finished hemp products at 0.4mg total THC per container misidentifies the problem: targeting compliant producers with USDA organic certification and years of third-party testing behind them rather than the bad actors mislabeling potency or skipping independent testing entirely. Mazza draws on Vitality CBD’s full-spectrum formulations to make the case that the proposed threshold would also eliminate science-backed products: Farm Bill 2018 research now confirms that full-spectrum extraction’s entourage effect delivers stronger therapeutic outcomes than CBD isolate, making the isolate carve-out lawmakers treat as a concession a genuine step backward. He proposes a three-part alternative — FDA oversight through the HEMP Act to remove dangerous products, a federal quality seal rewarding organic certification and transparent testing, and dosage-based rules that distinguish wellness applications from high-dose intoxicants, arguing that a sound regulatory framework for hemp must be built around the producers who have already proven they can meet the highest standards, as published in Business of Cannabis.

Writing for Wellbeing Magazine, Scott Mazza, co-founder of Vitality CBD, explores the therapeutic potential of CBD as a non-intoxicating intervention for neuropathy and chronic nerve pain. Mazza highlights emerging clinical research and peer-reviewed studies that demonstrate how high-quality, third-party-tested CBD can reduce pain intensity, improve sleep quality, and enhance mobility by interacting with the endocannabinoid system. Under his leadership, Vitality CBD emphasizes a holistic approach to nerve health, advocating for the use of organic, safely extracted topicals and salves to provide targeted relief for sensory discomfort.

Scott Mazza, co-founder of Vitality CBD, examines the shifting federal landscape for hemp regulations and the critical need for a permanent regulatory pathway through legislation like the HEMP Act. Writing for WholeFoods Magazine, Mazza details how “total THC” framework changes and synthetic cannabinoid bans threaten industry stability, impacting over 300,000 jobs and consumer access to hemp-derived wellness. His analysis underscores Vitality CBD’s commitment to transparent FDA oversight and high-quality production standards to ensure long-term market maturity and consumer safety.

In this WholeFoods Magazine column, Scott Mazza, co-founder of Vitality CBD, argues that while peer-reviewed research increasingly supports CBD’s potential for anxiety, pain, sleep, and inflammation, inconsistent production standards continue to undermine its medical credibility. Drawing on regulatory data and industry experience, Mazza outlines how contamination, inaccurate labeling, and lack of GMP compliance prevent CBD from being taken seriously by healthcare and policymakers. He calls for nuanced, science-aligned regulation (quality standards, mandatory testing, and federal certification) rather than blanket bans, to move CBD toward evidence-based wellness adoption.

In this Wellbeing Magazine article, Scott Mazza, co-founder of Vitality CBD and Certified Headies, explains why CBD salves and topicals have emerged as one of the most durable, science-aligned applications of cannabidiol as novelty products fade. Drawing on existing research and consumer use patterns, Mazza outlines how non-ingestible CBD interacts locally with the endocannabinoid system to support pain relief, inflammation reduction, muscle relaxation, and sleep-related routines. He also stresses the importance of product quality, third-party testing, and clean formulations, noting that regulatory gaps make consumer diligence essential when applying CBD directly to the skin.

In this Nutritional Outlook analysis, Scott Mazza, co-founder of Vitality CBD, examines market data showing a decline in novelty CBD products in gas stations and convenience stores as the hemp sector matures. Mazza explains that consumers are increasingly distinguishing between wellness-focused CBD, best delivered through formats like gummies and topicals, and recreational cannabinoids such as delta-8 and THCA, which better fit convenience retail channels. He frames this shift as a positive correction driven by consumer education, science-backed applications, and demand for quality, testing, and credible producers, as published in Nutritional Outlook.

In this Cannabis & Tech Today column, Scott Mazza, co-founder of Vitality CBD, argues that the future of hemp regulation under the Farm Bill 2025 must be guided by scientific evidence rather than political reaction. Drawing on industry experience, Mazza outlines how research increasingly supports CBD’s role in areas such as anxiety, sleep, and pain management, while warning that regulatory uncertainty and state-level bans undermine consumer trust and responsible operators. He calls for nuanced, science-based federal standards, focused on testing, labeling, and access, to protect consumers without reversing the progress made since hemp legalization, as published in Cannabis & Tech Today.

In this WholeFoods Magazine column, Scott Mazza, co-founder of Vitality CBD, examines how the upcoming Farm Bill 2025 could reshape the U.S. hemp and CBD market. Mazza outlines the risks posed by unclear federal guidance, state-by-state enforcement, and proposals such as a “total THC” standard, arguing that these moves threaten responsible operators as much as bad actors. He calls for coordinated, science-based regulation, rather than product bans, to protect consumers, establish quality standards, and support CBD’s transition from novelty product to legitimate wellness category, as published in WholeFoods Magazine.

In this Wellbeing Magazine article, Scott Mazza, co-founder of Vitality CBD and Certified Headies, explains how THCA differs from THC, why it is non-intoxicating in its raw form, and how heat-driven conversion creates both its psychoactive potential and legal complexity. Mazza details how THCA remains legal in the U.S. under the 2018 Farm Bill and in the U.K. due to its exclusion from controlled substance listings, while noting that proposed “total THC” standards could significantly alter its status. He emphasizes the need for clear, science-based regulation and consumer diligence, highlighting the importance of third-party testing and quality standards in an underregulated market.

In this industry analysis, Scott Mazza, co-founder and COO of Vitality CBD, explains the scientific, legal, and practical distinctions between THC and its acidic precursor, THCA, focusing on how heat-driven conversion determines psychoactivity and regulatory status. Mazza reviews early research pointing to THCA’s potential anti-inflammatory, anti-nausea, and neuroprotective properties, while clearly noting that most evidence remains preclinical. He also assesses the unstable U.S. regulatory environment, highlighting proposed federal and state-level changes that could reshape the legality of THCA and emphasizing the need for clear standards, testing, and consumer diligence.

In this Wellbeing Magazine article, Scott Mazza, Co-Founder of Vitality CBD and Certified Headies, explains what THCA is, how it differs from THC, and why it has emerged as a legally distinct hemp-derived cannabinoid under the 2018 Farm Bill. Mazza outlines early scientific research suggesting potential anti-inflammatory, neuroprotective, and anti-nausea properties, while emphasizing that findings remain preliminary. He also examines the evolving regulatory landscape, warning that proposed changes to federal hemp law could significantly impact THCA’s legality and arguing for clear, science-based regulation rather than blanket product bans.

In this science-forward overview, Scott Mazza, co-founder and COO of Vitality CBD, examines the emerging research landscape around minor cannabinoids such as CBN, CBG, THCA, and THCV. The article synthesizes early findings on their distinct pharmacological profiles and potential applications, from sleep, pain, and inflammation to neuroprotection and skin health, while situating these compounds within the broader concept of the entourage effect. Mazza also addresses regulatory and quality challenges, arguing that evidence-based policy and rigorous research are essential to responsibly unlocking the therapeutic and nutritional potential of hemp’s lesser-known cannabinoids.